Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Study to Evaluate Safety and Efficacy of Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 1/2a Study to Evaluate Safety and Efficacy of Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Jul 2018

At a glance

  • Drugs Vax-DC/MM (Primary) ; Cyclophosphamide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Jul 2018 New trial record
    • 10 Jan 2017 Results published in the Oncotarget
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top